Lead Product(s): Idursulfase beta
Therapeutic Area: Genetic Disease
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: General Atlantic
Deal Size: $98.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing February 18, 2020
The proceeds, will be used to accelerate and expand the CANbridge rare disease pipeline through internal development and external partnerships, further build CANbridge’s commercial infrastructure.